Cytokine therapy for craniosynostosis.
The birth prevalence of craniosynostosis (premature suture fusion) is 300-500 per 1,000,000 live births. Surgical management involves the release of the synostosed suture. In many cases, however, the suturectomy site rapidly reossifies, further restricts the growing brain and alters craniofacial growth. This resynostosis requires additional surgery, which increases patient morbidity and mortality. New findings in bone biology and molecular pathways involved with suture fusion, combined with novel tissue engineering techniques, may allow the design of targeted and complementary therapies to decrease complications inherent in high-risk surgical procedures. This paper selectively reviews recent advances in i) identifying genetic mutations and the aetiopathogenesis of a number of craniosynostotic conditions; ii) cranial suture biology and molecular biochemical pathways involved in suture fusion; and iii) the design, development and application of various vehicles and tissue engineered constructs to deliver cytokines and genes to cranial sutures. Such biologically based therapies may be used as surgical adjuncts to rescue fusing sutures or help manage postoperative resynostosis.
Mooney
Mark P
MP
Department of Oral Medicine and Pathology, School of Dental Medicine, 329 Salk Hall, University of Pittsburgh, Pittsburgh, PA 15261, USA. mpm4@pitt.edu
Moursi
Amr M
AM
Opperman
Lynne A
LA
Siegel
Michael I
MI
D002648:Child; D002675:Child, Preschool; D003398:Craniosynostoses / Q000145:classification / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*; D016207:Cytokines / Q000627:therapeutic use*; D005260:Female; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D007223:Infant; D011247:Pregnancy; D015398:Signal Transduction / Q000502:physiology; D014157:Transcription Factors / Q000502:physiology
D016207:Cytokines; D006133:Growth Substances; D014157:Transcription Factors